Nasal Loop Diuretic
A nasal loop diuretic is bumetanide nasal spray (ENBUMYST™), a formulation that delivers the loop diuretic bumetanide through nasal mucosa absorption rather than oral or intravenous routes 1.
What It Is
Bumetanide nasal spray represents a novel delivery method for loop diuretic therapy, approved in September 2025 in the USA for treating edema associated with:
- Congestive heart failure
- Hepatic disease
- Renal disease, including nephrotic syndrome 1
Key Advantages of Nasal Delivery
The nasal route offers more consistent and predictable bioavailability compared to oral administration, which is particularly valuable in patients with gastrointestinal impairment 1. This addresses a common clinical challenge since oral loop diuretics can have variable absorption, especially in patients with gut edema from heart failure or other conditions affecting intestinal perfusion.
Clinical Context
Loop diuretics remain the cornerstone of congestion management in heart failure. The 2022 AHA/ACC/HFSA guidelines emphasize that patients with evidence of congestion or fluid retention should receive diuretics to eliminate clinical signs of fluid retention using the lowest dose possible to maintain euvolemia 2.
Traditional bumetanide (oral form) is already recognized as having superior oral bioavailability compared to furosemide, with some patients responding more favorably to bumetanide or torsemide due to their increased bioavailability 2. The nasal formulation potentially enhances this advantage further.
Mechanism of Action
Like all loop diuretics, bumetanide works by inhibiting the Na+/K+/2Cl- cotransporter in the thick ascending limb of the loop of Henle 3. The nasal spray delivers the same pharmacologic effect but through a different absorption route.
Important Caveats
- This is designed as a short-term therapeutic option 1
- While the delivery route is novel, bumetanide nasal spray should still be combined with other guideline-directed medical therapy for heart failure, as diuretics alone do not reduce mortality 2
- The treatment goal remains the same: eliminate clinical evidence of fluid retention while maintaining euvolemia 2